Search results: (10000)
News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice – Results of the STAR-RA Study
Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.
News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
News Hemophilia and Intensive Physical Activity Are Not Mutually Exclusive − Case Report of a Top Athlete
Traditionally, many doctors have been reluctant to allow men with hemophilia to engage in more intense physical activity, mainly due to concerns about bleeding caused by overexertion or injury. Today's prophylactic modalities, however, allow for prevention to be set in such a way that the risk of bleeding is significantly reduced. Modern treatment thus brings hope for hemophiliacs to participate in some sports that were previously not recommended. In addition to effective prophylaxis, appropriate training activities, developed with the participation of a physiotherapist and sports doctor, are also crucial.
News When Size Matters or What Is Small Is Effective
The systemic effect of an orally administered drug can be expected, among other things, if it has suitable physicochemical properties. How can insufficient absorption or poor solubility be solved? We provide the answer below.
News Immunotherapy of Cancer Diseases
Immunotherapeutic strategies have been successfully utilized recently in the treatment of various malignancies. Increasing understanding of the interactions between the tumor and the host organism over the last few years has led to proposals of various promising therapeutic approaches. This overview briefly summarizes the basic principles of immunotherapy for cancer diseases.
News No deficiency of essential fatty acids in home parenteral nutrition
A Dutch-British study, the results of which were published in the Journal of Parenteral and Enteral Nutrition, addressed the issue of potential deficiency of essential fatty acids in patients using home parenteral nutrition.
News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).
News Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.
News Therapy Change from Adalimumab to Baricitinib in Patients with Rheumatoid Arthritis
The aim of the presented analysis of data from the RA-BEAM study was to evaluate the clinical response of patients who were switched to baricitinib during the study due to an inadequate response to adalimumab.
News Effect of Combination Therapy on Symptoms of Allergic Rhinitis
The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active ingredients, compared to placebo and monotherapies during a 14-day therapy in adult and adolescent patients with allergic rhinitis.
News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy
The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.
News Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.
News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience
The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.
News Can Erdostein Help in Treating Infections Related to Biofilm Formation?
One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?
News Adding Paracetamol to Tramadol to Relieve Early Postoperative Pain After Lumbar Discectomy
A recently published study is likely the first prospective randomized controlled trial comparing the postoperative analgesic efficacy of a tramadol and paracetamol combination versus tramadol alone. Its results favor the combination, with significantly lower pain scores during the first 30 minutes and reduced tramadol consumption within the first 24 hours post-surgery.
News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU
In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.
News Candesartan Could Ameliorate the Cytokine Storm in COVID-19 Infection
Scientists from Bethesda, USA, experimentally found the upregulation of the same genes during COVID-19 infection as with the action of glutamate (simulating aging and Alzheimer's disease) and the normalization of their expression by candesartan. Considering that many of these genes are involved in the cytokine storm in COVID-19, the mentioned results support the hypothesis that sartans − or at least candesartan − could mitigate the cytokine storm in patients with severe COVID-19.
News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.
News MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information
How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship with multiple sclerosis be? This unusual topic was explored in a publication in the journal Neurosciences.
News Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children
Children are frequent carriers of pneumococci, which can cause both common non-invasive and more severe, life-threatening invasive pneumococcal diseases, especially in children under 1 year of age and in people over 65 years old. Almost a year ago, a pediatric indication for a 15-valent pneumococcal vaccine was approved, which is enriched with 2 new serotypes and, according to study results, appears to be potentially more effective even in protecting against serotype 3. So what are the vaccination options for healthy immunocompetent children, and what benefits does this vaccine offer for premature infants? Professor Roman Chlíbek, chair of the Czech Vaccinology Society ČLS JEP, answered these questions in his presentation at the June Interdisciplinary Conference of PLDD.